Hence, targeting IL-6 or PGE2 reduced DNMT3B induction and enhanced the efficacy of programmed cell death protein 1 (PD-1) immunotherapy in preclinical mouse models of breast cancer metastasis [92]. The gene discussed is DNMT3B; the disease is breast carcinoma.